Zenas BioPharma, Inc.
NASDAQ:ZBIOBiotechnology
+$0.64 today
- Market cap
- $1.79B
- Beta
- -0.69
- P/E (TTM)
- -2.5
- EPS (TTM)
- -$7.64
Volume 0.48M
Average 0.71M
ZBIO Long-term Debt
Borrowings due after more than one year.
Zenas BioPharma, Inc.NASDAQ: ZBIO
Long-term Debt · Q1 FY2026 · quarter ended Mar 2026
Long-term debt remains negative
Q1 FY2026 long-term debt was $350.62M, compared with $0 a year earlier.
Context
- Long-term debt amounted to 46.9% of total assets at the end of Q1 FY2026, up 46.9 pp from a year earlier.
- Long-term debt increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Long-term Debt history
USD · from the balance sheet
- Latest · FY2025
- 78.64M USD
- Year-over-year change
- —
| Period | Period end | Long-term Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 78.64M | — |
| FY2024 | 2024-12-31 | 0 | -100.0% |
| FY2023 | 2023-12-31 | 20.3M | — |
| FY2022 | 2022-12-31 | 0 | — |
Long-term Debt vs competitors
How ZBIO compares with its peers on the latest reported figures
- ZBIO's Mar 2026 long-term debt of $350.62M is the highest of the 8 companies compared; the peer median is $0.
- Long-term debt amounts to 46.9% of total assets for ZBIO, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $350.62M | — | — | 46.9% | |
| Mar 2026 | $4.75M | -40.9% | -11.9% | 7.5% | |
UPBUpstream Bio, Inc. | Mar 2026 | $390K | — | — | 0.1% |
| Sep 2026 | $0 | — | — | 0.0% | |
TRAXFirst Tracks Biotherapeutics Inc | Mar 2026 | $0 | — | — | 0.0% |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Dec 2025 | $0 | — | — | 0.0% | |
| Peer median (excluding ZBIO) | $0 | -40.9% | -11.9% | 0.0% | |
Competitors are the stored peer set for ZBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Zenas BioPharma, Inc.
NASDAQ:ZBIO
Intrinsic Alpha fair value
Locked
Current Price
$26.42
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.